Search

Displaying results 3371 - 3380 of 10000 in total
  1. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.

  2. Drug

    Hyoscyamine

    go.drugbank.com/drugs/DB00424
    ApprovedInvestigational

    [L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] … Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine].[A228423] It is commonly extracted from plants in the _Solanaceae_ or nightshade family.

    Mixtures: UR N-C Urinary Antiseptic
  3. Drug

    Phenacemide

    go.drugbank.com/drugs/DB01121
    Approved

    Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.

  4. Drug

    Embusartan

    go.drugbank.com/drugs/DB19949
    Experimental

    Embusartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

    Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor Blockers
  5. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    Growth hormone is a peptide hormone secreted by the pituitary gland that plays a crucial role in promoting longitudinal growth during childhood and adolescence and regulating metabolic function in adulthood … [A241485] Somatrogon was produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology.

  6. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation.

  7. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255]. … A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257].

  8. Drug

    Practolol

    go.drugbank.com/drugs/DB01297
    Approved

    A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.

    Synonyms: N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide
  9. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].

  10. Drug

    Bisacodyl

    go.drugbank.com/drugs/DB09020
    ApprovedInvestigational

    Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation. … [A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956[L33045] but has been used as a laxative since 1952.[A233300]